Please assess the completion status of the following clinical trial:

Trial Title: Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically confirmed CD30-positive hematologic malignancy.~* Patients with HL must have failed systemic chemotherapy either as induction therapy for advanced stage disease or salvage therapy after initial radiotherapy for early stage disease and were ineligible for, refused treatment by, or previously received stem cell transplant.~* Patients must have measurable disease of at least 10mm as documented by radiographic technique.~* Must be at least 18 years of age.~Exclusion Criteria:~* Patients with current diagnosis of pcALCL (systemic ALCL eligible).~* Patients with history of allogeneic stem cell transplant.~* Patients who have had previous treatment with any anti-CD30 antibody.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).